Connect Biopharma

CNTB · Nasdaq · United States

Share price · CNTB

$0.67-1.76 (-72.63%) 3M

close as of 2026-11-18 · 24h delayed · vol 681K (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CNTB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 15 Sep 2026-32.2%
  2. 14 Sep 2026-15.4%

    Nothing announced by CNTB that day or the session before.

  3. 3 Sep 2026-30.1%

    Nothing announced by CNTB that day or the session before.

  4. 2 Sep 2026+16.9%
  5. 13 Aug 2026+9.0%
  6. 9 Jul 2026+19.8%
  7. 7 Jul 2026-6.4%

    Nothing announced by CNTB that day or the session before.

  8. 12 May 2026+14.5%
  9. 30 Mar 2026-15.9%
  10. 26 Mar 2026+9.8%

    Nothing announced by CNTB that day or the session before.

Share of unusual movement by asset

For each asset, the share of CNTB's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Rademikibart
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—14%
Other company news (earnings, financing, releases naming no asset)—7%
Sessions with no dated event—78%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
IL-4R-alphaMonoclonal antibody
Atopic DermatitisChronic Obstructive Pulmonary DiseaseAsthma

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
RademikibartPhase 3Asthma; Eosinophilic
Est. primary completion 2026-12-31 · NCT06488755 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 September 2026Topline resultRademikibartPhase 2 Seabreeze STAT COPD topline results
Connect Biopharma · Source ↗
15 September 2026Topline resultRademikibartPhase 2 acute asthma exacerbation topline results
Connect Biopharma · Source ↗
30 March 2026Topline resultRademikibartRADIANT-AD (NCT06477835) Phase 3 met its primary endpoint
Simcere Pharmaceutical Group Limited (2096.HK) · Source ↗
9 July 2025Filing submittedRademikibartSimcere submits rademikibart NDA in China for atopic dermatitis
CN, NMPA · Source ↗
8 July 2025Filing acceptedRademikibartNMPA accepts Simcere's NDA for rademikibart in atopic dermatitis
CN, NMPA · Simcere Pharmaceutical · Source ↗

Financial reports

Quarterly & interim (8)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$2.8M$16M$27M+ $4.5M short-term inv.$17M-$16M operating cash flowreport ↗
View 7 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$0.2M$15M$46M+ $0 short-term inv.$19M-$16M operating cash flowreport ↗
2025-Q3<$0.1M$11M$38M+ $17M short-term inv.$17M-$17M operating cash flowreport ↗
2025-Q2$0.1M$8.8M$41M+ $31M short-term inv.$13M-$13M operating cash flowreport ↗
2025-Q1$0$6.6M$48M+ $36M short-term inv.$10M-$10.0M operating cash flowreport ↗
2024-Q3$1.2M$9.0M$97M$13M-$13M operating cash flowreport ↗
2024-Q2$24M$5.3M$110M—-$7.7M operating cash flowreport ↗
2024-Q1—$8.7M$114M$8.7M-$0.6M operating cash flowreport ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0.1M$38M$38M+ $6.0M short-term inv.$14M-$51M operating cash flowreport ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$26M$29M$78M+ $15M short-term inv.$3.9M-$24M operating cash flowreport ↗
2023-FY$0$53M$106M+ $13M short-term inv.$16M-$48M operating cash flowreport ↗
2022-FY——$79M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 2 purchases ($4.4M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-30LIU JEAN I · directorAward / grant8,984——Form 4
2026-09-30Xanthopoulos Kleanthis Gabriel · directorAward / grant5,000——Form 4
2026-06-30LIU JEAN I · directorAward / grant6,718——Form 4
2026-06-30Xanthopoulos Kleanthis Gabriel · directorAward / grant3,738——Form 4
2026-05-29Huang James · directorOpen-market purchase150,000$2.48$372KForm 4
2026-03-31LIU JEAN I · directorAward / grant5,061——Form 4
2026-03-31Xanthopoulos Kleanthis Gabriel · directorAward / grant2,816——Form 4
2026-03-31Huang James · directorOpen-market purchase1,160,000$3.45$4.0MForm 4